Adtran unlocks full potential of ZR and ZR+ optics with FSP 3000 M-Flex800™
Adtran today launched its FSP 3000 M-Flex800™, enabling network operators to unlock the full potential of ZR and ZR+ optics for high-capacity transport solutions across edge, metro and core networks. This single-slot card – the newest addition to Adtran’s coherent optical technology suite – offers a universal host for ZR and ZR+ optics and addresses many of the shortfalls of IP-over-DWDM (IPoWDM) solutions. Compared to classical OTN muxponder solutions, M-Flex800™ supports much simpler demarcation and multiplexing technology. Combined with the use of a wide range of ZR optics, this enables a new way to develop compact and low-power transport solutions from the edge to the core. This new IP-to-DWDM approach enables flexible, cost-efficient networking with separated IP and optical layers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321282596/en/
Adtran’s FSP 3000 M-Flex800™ is a one-slot card that acts as a universal host for ZR, ZR+ and OpenROADM coherent interfaces. (Photo: Business Wire)
“Initially developed for DCI, ZR optics are now expanding their reach into diverse operational environments. Today’s launch will be key in that transition. Our new FSP 3000 M-Flex800™ will be a gateway between classical DWDM and the latest IPoDWDM, bringing the benefits of standardized ZR optics to a broad spectrum of operators,” said Christoph Glingener, CTO of Adtran. “Our versatile one-slot card acts as a universal host for ZR, ZR+ and OpenROADM coherent interfaces, seamlessly integrating into any open line system and enabling multiple use cases. Whether you’re looking to deploy in carrier infrastructure or DCI environments, in central offices or street cabinets, our M-Flex800™ can be easily slotted into any FSP 3000 chassis.”
The Adtran FSP 3000 M-Flex800™ is a versatile, multi-rate line card able to support an extensive range of grey and coherent interfaces, including 100Gbit/s, 400Gbit/s, 800Gbit/s, ZR, ZR+, OpenROADM and other types of coherent optics. Designed to meet the high-capacity connectivity needs of telecom operators, cloud providers and enterprises, it facilitates a range of applications from the edge to the core. This universal host simplifies upgrades to 800Gbit/s line speeds and Ethernet services and can multiplex 100GbE, 400GbE and OTU4 services into line speeds up to 800Gbit/s. Suited for tasks such as IP and optical demarcation, ZR-to-ZR interconnects and edge OTN applications, the Adtran FSP 3000 M-Flex800™ offers a cost-effective and low-power solution in a single-slot card.
“With its exceptional flexibility, operational simplicity and compact footprint, our FSP 3000 M-Flex800™ caters to diverse environments, from data centers to space-restricted street cabinets. Its ability to reduce power consumption while supporting high-capacity, open and scalable transport is a testament to our commitment to driving the next generation of transport infrastructure,” commented Ryan Schmidt, GM of optical transport at Adtran. “We’re addressing the core needs of network operators across a broad spectrum of applications, even beyond the traditional transponder/muxponder use cases. Today’s launch marks a big step towards more efficient, versatile and cost-effective infrastructure.”
Further information on the FSP 3000 M-Flex800™ is available in these slides.
A supporting product video is also available to watch.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321282596/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Scientek Corporation Sign Reseller Agreement to Boost Quantum Computing in Taiwan18.9.2025 11:11:00 EEST | Press release
IQM Quantum Computers and Scientek Corporation, a Taiwan-based reseller of scientific instruments and other high-technology products, today announced the signing of a strategic reseller agreement to accelerate the commercialisation of quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918110284/en/ IQM and Scientek Corporation sign reseller agreement The agreement follows the installation of IQM Spark, the first full-stack superconducting quantum computer at the Taiwan Semiconductor Research Institute (TSRI). Under the reseller agreement, Scientek will sell and promote IQM’s on-premises quantum computers and cloud solutions that meet the evolving needs of universities, research institutions, and enterprises. Combining Scientek's strong market presence and customer-centric approach in Taiwan with IQM’s quantum leadership, the collaboration will help Taiwanese businesses and research institutions to explore a
Acuity Knowledge Partners Acquires Ascent18.9.2025 10:30:00 EEST | Press release
Acuity Knowledge Partners (Acuity), a leading global provider of bespoke research, data management, analytics and AI solutions to the financial services sector, has announced that it has exchanged on the acquisition of Ascent. The transaction is expected to close on 30th September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915732380/en/ L-R: Stewart Smythe, Chief Executive Officer, Ascent; Jon O'Donnell, Chief Operating Officer, Acuity Knowledge Partners, and Robert King, Chief Executive Officer, Acuity Knowledge Partners This strategic move significantly expands Acuity's Data and Technology Services (DTS) division and its offering of technology and AI led services and solutions. Ascent, a leading European provider of AI-powered digital transformation services, supports over 170 clients globally, with 550 data, software, and cloud specialists operating across seven European jurisdictions. “Our acquisition of Asc
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 09:00:00 EEST | Press release
Almirall, S.A. (ALM) a global biopharmaceutical company focused on medical dermatology today announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris. POSITIVE is the first RWE study in dermatology to use the World Health Organization Well-Being Index (WHO-5) as a primary endpoint. The selection of the abstract as a late breaker at the EADV congress highlights the importance of the findings of the POSITIVE study and its unique approach to evaluating the long-term holistic impact of an advanced treatment in patients with moderate-to-severe psoriasis, a condition that profoundly impairs social, psychological, and physical quality of life, impacting overall well-being1. Two‑Year Real‑World Results from POSITIVE The 24-month, multinational, phase IV observational study enrolled 785 adult patients with moderate-to-severe plaque psoriasis across nine European countries
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 09:00:00 EEST | Press release
Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with confidence. This joint offering provides an end-to-end solution designed to meet evolving regulatory expectations, accelerate adoption
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 08:00:00 EEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom